Advanced Filters
noise

pleural-effusion Clinical Trials

A listing of pleural-effusion medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 30 clinical trials
K Ken Ka Pang Chan

Prospective Evaluation of Patients With Pleural Effusion

Having a pleural effusion is a common reason for being hospitalized, as it usually requires in-patient care for invasive diagnostic and therapeutic procedures. Specific subtypes of pleural effusion may warrant recurrent admissions, a longer hospital stay and consume more healthcare resources. Despite the recent advancement of pleural medicine, better research …

18 - 100 years of age Both Phase N/A
E Emma P Hedley

Prospective Data Collection on Clinical, Radiological and Patient Reported Outcomes After Pleural Intervention

The PROSPECT study aims to look at the number of problems or side effects which occur after patients have had a procedure completed to remove fluid or air from the space between the lung and the chest wall. Other information will also be collected to see whether anything else affects …

18 - 100 years of age Both Phase N/A
C Corinne Levy, MD

Pneumonia and Empyema in Emergency Departments in Children

Describe the epidemiology of hospitalized pediatric pneumonia and pneumonia with pleural effusion: frequency, clinical and biological characteristics, responsible bacteria and pneumococcus place, antibiotic resistance, treatment, vaccine status.

1 - 15 years of age Both Phase N/A
L Luz Cuaboy

UNC Pleural Fluid Registry

Research with biospecimens such as blood, tissue, or body fluids can help researchers understand how the human body works. Researchers can make new tests to find diseases, understand how treatments work, or find new ways to treat a disease. The purpose of this study is to collect biospecimens for research …

18 - 100 years of age Both Phase N/A
S Sze Shyang Kho, MD

A Prospective Observational Study on the Role of Transthoracic Ultrasound in Differentiating Tuberculous From Malignant Pleural Effusion

Primary Endpoint To assess the prevalence and diagnostic performance of pre-determined echographic features in predicting the diagnosis of TBE from MPE. To determine the clinical, pleural fluid and echographic parameters that were different among TBE and MPE and to establish a clinical prediction model for TBE. Secondary Endpoint To assess …

18 - 100 years of age Both Phase N/A
Y Yeon Wook Kim, MD, PhD

Longitudinal Follow up of Patients With Pleural Effusion

This study aims to evaluate the clinical course of patients diagnosed with pleural effusion and determine various clinical factors and biomarkers associated that can predict the diagnosis and clinical outcome and prognosis of patients with pleural effusion due to specific causes.

- 100 years of age Both Phase N/A
C Christopher Chan, MBChB

Comparing N-terminal-proB-type Natriuretic Peptide With Other Criteria in Pleural Fluid Analysis

To assess the discriminative properties of pleural fluid (PF) N-terminal-proB-type-natriuretic-peptide (NTproBNP) levels in identifying heart failure (HF)-associated pleural effusions (PE).

18 - 100 years of age Both Phase N/A

Indwelling Pleural Catheters With or Without Doxycycline in Treating Patients With Malignant Pleural Effusions

This study is designed to obtain preliminary data comparing indwelling pleural catheters (IPCs) versus IPCs plus doxycycline for pleurodesis as treatments for malignant pleural effusion (MPE). Indwelling pleural catheters (IPCs) are commonly used to treat pleural effusions (build-up of fluid in the lungs). Doxycycline is an antibiotic that is also …

18 - 100 years of age Both Phase N/A
G Gabrielle Drevet, MD

Pleural Carcinomatosis Tissue Banking

Malignant pleural effusion is a common evolution of various cancers and is associated with poor prognosis and quality of life. About 28% of patients with primary malignancy will develop pleural metastasis. Malignant pleural effusion mostly occurs in lung, breast, ovarian and gastric cancers. Median survival ranges from 3 to 13 …

18 - 110 years of age Both Phase N/A
S Sarah Ginn

Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)

The primary objective of this study, sponsored by Travera Inc. in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using isolated tumor cells from various specimen formats including malignant fluids such as pleural effusions and ascites, …

18 - 100 years of age Both Phase N/A

Rewrite in simple language using AI